Literature DB >> 1603818

Misoprostol therapy following trinitrobenzene sulfonic acid-induced colitis accelerates healing.

K J Torsher1, L R Empey, R N Fedorak.   

Abstract

Prostaglandins have been demonstrated to have a mucosal protective effect when administered prior to the experimental induction of colitis in animals. We here determined whether prostaglandins would have a beneficial therapeutic effect when administered after colitis had been established. Diffuse, chronic, trinitrobenzene sulfonic acid-induced colitis was established in rats, and misoprostol was administered daily for up to 10 days following the induction of colitis. The effects of misoprostol therapy were compared to those obtained by treatment with 5-aminosalicylic acid and betamethasone. Misoprostol therapy following trinitrobenzene sulfonic acid-induced colitis accelerated colonic healing, as measured in terms of macroscopic ulceration area and fluid absorption, whereas 5-aminosalicylic acid and betamethasone therapy did not. Ileal fluid absorption impairment was repaired by betamethasone but not by misoprostol or 5-aminosalicylic acid therapy.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1603818     DOI: 10.1016/0952-3278(92)90083-u

Source DB:  PubMed          Journal:  Prostaglandins Leukot Essent Fatty Acids        ISSN: 0952-3278            Impact factor:   4.006


  3 in total

1.  Misoprostol protects mice against severe Clostridium difficile infection and promotes recovery of the gut microbiota after antibiotic perturbation.

Authors:  Joseph P Zackular; Leslie Kirk; Bruno C Trindade; Eric P Skaar; David M Aronoff
Journal:  Anaerobe       Date:  2019-06-17       Impact factor: 3.331

2.  The effect of local attachment of cationized antioxidant enzymes on experimental colitis in the rat.

Authors:  S Blau; R Kohen; P Bass; A Rubinstein
Journal:  Pharm Res       Date:  2000-09       Impact factor: 4.200

3.  Mucosal protective activity of prostaglandin analogs in rodent colonic inflammation.

Authors:  D J Fretland; D L Widomski; C P Anglin; R E Walsh; S Levin; A F Gasiecki; P W Collins
Journal:  Inflammation       Date:  1992-12       Impact factor: 4.092

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.